Hemolysis refers to the damage of red blood cells leading to the release of intracellular erythrocyte content into blood plasma. Erythrocytes comprise approximately 45% of whole blood by volume. When hemolysis occurs in vivo, it can lead to anemia, jaundice and other pathological conditions which could become life threatening. Hemoglobin is a dominant intracellular protein of erythrocytes. It plays a key role in carrying oxygen to other cells and tissues. However, extracellular hemoglobin released upon hemolysis is toxic and may affect vascular, myocardial, renal and central nervous system tissues. Therefore, all medical devices and drugs which come into contact with blood are required to be tested for potential hemolytic properties.

• NCL_Method_ITA-1_May2020.pdf(PDF | 644 KB)

Researchers should cite this work as follows:

• Barry Neun, Anna Ilinskaya, Marina Dobrovolskaia (2020). NCL Method ITA-1. (Version 2.0b). NCI Hub. doi:10.17917/V9AP-D094

  BibTex | EndNote

1. hemolysis
2. Nanoparticles